Furthermore, it is worth exploring the efficacy of other therapeutic strategies against NECC: PD-L1 inhibitors and the combination of PD-1/PD-L1 inhibitors with therapeutic cancer vaccines, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), or other targeted therapies. This evidence concerns the gene PDCD1 and cancer.